Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome

van Kraaij, Tom and Mostard, Rémy and Ramiro, Sofia and Magro Checa, Cesar and van Dongen, Christel and van Haren, Eric H. J . and Buijs, Jacqueline and Landewé, Robert (2020) Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. European Journal of Case Reports in Internal Medicine, 7 (5). ISSN 2284-2594

document (1).pdf - Published Version

Download (408kB) | Preview
Official URL:


Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a treatment for COVID-19-associated CRS. We present a case of life-threatening CRS caused by COVID-19 infection with a favourable response to immunosuppressive therapy with tocilizumab (TCZ). The rapid clinical and biochemical improvement following TCZ administration suggests that treatment with immunotherapy can be life-saving in selected patients with COVID-19-induced CRS.

Item Type: Article
Uncontrolled Keywords: COVID-19, cytokine release syndrome, tocilizumab
Subjects: 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale)
Depositing User: Chiara D'Arpa
Date Deposited: 24 Nov 2020 13:58
Last Modified: 24 Nov 2020 13:58

Actions (login required)

View Item View Item